


**EN1/FANDANGO**

**Sponsor: NSGO**

**A randomised double-blind placebo-controlled phase II trial of first line combination chemo-therapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer**

Study Design:



**Stratification:**

- Stage of disease (stage 3C 2 vs. stage 4 vs. recurrent disease)
- Prior adjuvant chemotherapy (yes/no)
- Disease status (Measurable vs. non-measurable disease according to RECIST 1.1)

**Planned No. of patients: 148**

**Current accrual: 127**

Other important information: Status - recruiting